Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02901067 · ClinicalTrials.gov registry record · Phase 2
STAT-STatin and Aspirin in Trauma
A Phase 2 study, sponsored by Denver Health and Hospital Authority.
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT02901067 is a Phase 2 study that was terminated before completion, run by Denver Health and Hospital Authority. The registered enrollment target is 43 participants.
The verdict
NCT02901067, a Phase 2 study, was terminated before completion, sponsored by Denver Health and Hospital Authority.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is a phase II, pragmatic, prospective, randomized, double-blind, adaptive clinical trial examining the efficacy of statins and aspirin in the reduction of acute lung injury and venous thromboembolism in patients with fibrinolysis shutdown.
Interventions
- DRUG Aspirin and Rosuvastatin
- DRUG Placebo (for Aspirin and Rosuvastatin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2017-02-03 |
| Est. Completion | 2021-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02901067
The ClinicalTrials.gov registry entry for NCT02901067 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Denver Health and Hospital Authority, which has 73 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aspirin and Rosuvastatin is the first listed.
NCT02901067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02901067 about?
NCT02901067 is a clinical study titled "STAT-STatin and Aspirin in Trauma". This is a phase II, pragmatic, prospective, randomized, double-blind, adaptive clinical trial examining the efficacy of statins and aspirin in the reduction of acute lung injury and venous thromboembolism in patients with fibrinolysis shutdown.
What is the current status of trial NCT02901067?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2017-02-03. Estimated completion is 2021-08-01.
What interventions are being tested in trial NCT02901067?
The interventions under investigation include: Aspirin and Rosuvastatin (DRUG), Placebo (for Aspirin and Rosuvastatin) (DRUG).
Who is sponsoring clinical trial NCT02901067?
This trial is sponsored by Denver Health and Hospital Authority, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.